These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 35344679

  • 1. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, Petitjean A, Dibarboure H, Lopez JG.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2050653. PubMed ID: 35344679
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez JG.
    Vaccine; 2021 Jul 05; 39(30):4144-4152. PubMed ID: 34130885
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E.
    Hum Vaccin Immunother; 2018 Jul 05; 14(8):1867-1873. PubMed ID: 29708843
    [Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.
    Value Health; 2016 Dec 05; 19(8):964-975. PubMed ID: 27987647
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H, Yang J, Chen ZY, Gong H, Zhong GJ, Yu HJ.
    Zhonghua Yi Xue Za Zhi; 2021 Aug 10; 101(30):2405-2412. PubMed ID: 34404135
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH, Ming WK, Chan PK.
    BMC Infect Dis; 2014 Nov 25; 14():618. PubMed ID: 25420713
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.
    Urueña A, Micone P, Magneres C, Mould-Quevedo J, Giglio N.
    Vaccines (Basel); 2021 Apr 01; 9(4):. PubMed ID: 33916048
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH, Ming WK, Chan PK.
    Hum Vaccin Immunother; 2015 Apr 01; 11(3):564-71. PubMed ID: 25714506
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E.
    Infect Dis Ther; 2015 Dec 01; 4(4):459-87. PubMed ID: 26350238
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G, Gregg M, Poulsen Nautrup B.
    J Med Econ; 2015 Dec 01; 18(9):746-61. PubMed ID: 25903831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.